ActivX Biosciences reports key findings that could impact the use of clinically approved CDK4/6 inhibitors in the treatment of cancer patients LA JOLLA, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- ActivX Biosciences, Inc., a wholly-owned subsidiary of Kyorin Pharmaceutical Co., Ltd. (Tokyo), announces a report published in a high profile,...

ActivX Biosciences’ KiNativ® platform featured in two articles demonstrating the importance of native kinase profiling for characterizing protein degraders LA JOLLA, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- ActivX Biosciences, Inc., a wholly-owned subsidiary of Kyorin Pharmaceutical Co., Ltd. (Tokyo), announces two reports published in high profile,...

ActivX Biosciences, Inc. Appoints Hugh Rosen Chairman & President; John Kozarich Transitions to New Role LA JOLLA, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- ActivX Biosciences, Inc.®, a wholly owned subsidiary of Kyorin Pharmaceutical Co., Ltd. (Tokyo), announces the appointment of Professor Hugh Rosen...